Inhibrx Biosciences, Inc. income statement

In fiscal 2025, Inhibrx Biosciences, Inc. reported revenue of $1.3m, up 550.0% on the year before, operating income of −$135m (a -10386.5% margin) and net income of −$140m, or −$9.04 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Inhibrx Biosciences, Inc.: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	2	0	1
Research and development	192	204	113
General and administrative	29	128	23
Operating income	−219	−331	−135
Interest expense	32	13	12
Income before tax	−240	1,688	−140
Income tax	0	0	0
Net income	−241	1,688	−140
Diluted EPS	−$20.48	$112.62	−$9.04
Diluted shares (average)	12m	15m	15m
EBITDA	−218	−329	−133

US$ millions unless shown otherwise. Fiscal quarters.

Inhibrx Biosciences, Inc.: income statement, quarterly
Quarter	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q2Jun 2026
Revenue	0	0	0	0	1	0	0	0
Research and development	68	39	33	37	22	29	25	24
General and administrative	93	8	17	6	6	5	6	8
Operating income	−161	−47	−50	−43	−27	−34	−31	−32
Interest expense	5	0	0	3	3	3	3	6
Income before tax	1,858	−44	−48	−43	−29	−35	−33	−37
Income tax	0	0	0	0	0	0	0	0
Net income	1,858	−44	−48	−43	−29	−35	−33	−37
Diluted EPS	$125.48	−$2.84	−$4.47	−$2.80	−$1.85	−$2.28	−$2.11	−$2.34
EBITDA	−160	−46	−49	−42	−27	−33	−30	−32

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DARE vs INBX INBX vs LGVN INBX vs RNAC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inhibrx Biosciences, Inc.